Connect Biopharma/$CNTB
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Connect Biopharma
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
- Ticker
- $CNTB
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 64
- Headquarters
- San Diego, United States
- Website
- www.connectbiopharm.com
CNTB Metrics
BasicAdvanced
$48M
-
-$1.19
-
-
Price and volume
Market cap
$48M
52-week high
$3.82
52-week low
$0.73
Average daily volume
7.5M
Financial strength
Current ratio
2.369
Quick ratio
2.113
Long term debt to equity
0.008
Total debt to equity
0.022
Profitability
EBITDA (TTM)
-69.729
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-2,336.30%
Operating margin (TTM)
-2,384.49%
Effective tax rate (TTM)
-0.28%
Revenue per employee (TTM)
$50,000
Management effectiveness
Return on assets (TTM)
-69.75%
Return on equity (TTM)
-140.51%
Valuation
Price to revenue (TTM)
15.006
Price to book
1.8
Price to tangible book (TTM)
1.8
Price to free cash flow (TTM)
-0.731
Free cash flow yield (TTM)
-136.83%
Free cash flow per share (TTM)
-1.049
Growth
Revenue change (TTM)
50.28%
Earnings per share change (TTM)
46.94%
3-year earnings per share growth (CAGR)
-11.02%
What the Analysts think about CNTB
Analyst ratings (Buy, Hold, Sell) for Connect Biopharma stock.
Analyst projections of the future price of Connect Biopharma stock.
CNTB Financial Performance
Revenues and expenses
CNTB Earnings Performance
Company profitability
Upcoming events
No upcoming events
CNTB News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.